The signalling pathways that link G-protein-coupled receptors to mitogen-activated protein kinases involve receptor and nonreceptor tyrosine kinases and protein kinase C (PKC). We explored the pathways that are implicated in the thromboxane (TX) A 2 -dependent activation of extracellular-signal-regulated protein kinase (ERK) and the role of the two TX receptor (TP) isoforms, TPα and TPβ. ERK activation by IBOP, a TX analogue, was dependent on epidermal-growth-factor receptor (EGFR) in TPα-or TPβ-transfected cells and in human aortic smooth muscle cells (hASMCs), since AG1478, a selective inhibitor of tyrosine phosphorylation of the EGFR, strongly blocked ERK and EGFR phosphorylation. In addition, EGFR transactivation leading to ERK activation involved matrix metalloproteinases (MMPs), since BB2516, an inhibitor of MMP, decreased ERK and EGFR phosphorylation in TPα-or TPβ-transfected cells. Moreover, we showed that both isoforms activate ERK phosphorylation in an Src-kinase-dependent manner, whereas PKC was mainly implicated in ERK activation and EGFR phosphorylation by TPβ. In hASMCs, we showed that ERK activation depended on both pertussis-sensitive and -insensitive Gα-proteins. We demonstrated further that EGFRs, PKC, Src kinase and MMPs are involved in ERK activation by TX. The results of the present study highlight a role for MMPs and PKC in EGFR transactivation triggered by the TPs and demonstrate this mechanism for the first time in primary cells, i.e. hASMCs.
INTRODUCTION
A diverse group of agonists, including peptide hormones, neurotransmitters and lipids, act through the G-protein-coupled receptors (GPCRs) to activate receptor tyrosine kinases (RTKs) and induce cell proliferation and differentiation. Extracellularsignal-regulated kinase (ERK) activation has been reported to be involved in receptor activation of multiple heterotrimeric G-proteins, including both pertussis toxin (PTX)-insensitive Gα q and -sensitive Gα i/o [1] [2] [3] . Although the signalling pathways that are involved in ERK activation can be subject to differential regulations between the different cellular systems, it is generally thought that activation of Gα q -coupled receptors involves protein kinase C (PKC), whereas Gα i/o -coupled receptors involve the β and γ subunits of G-proteins and c-Src-dependent activation of Ras [4, 5] . Characterization of the activation of RTKs by GPCRs demonstrated the involvement of the activation of the epidermalgrowth-factor (EGF) receptor (EGFR) [6, 7] or the plateletderived-growth-factor receptor (PDGFR) [6] , independently of detected exogenous growth factor. In some cellular models, this transactivation also implicated the activation of matrix metalloproteinases (MMPs) and the shedding of heparinbinding EGF(HB-EGF), one of the ligands of the EGF receptor (EGFR) [8] [9] [10] [11] . This transactivation of the RTK has a role in 1 These authors contributed equally to this work. 2 To whom correspondence should be addressed (e-mail ah31@aub.edu.lb).
ERK activation and subsequent DNA synthesis and expression of transcription factors [12] . Thromboxane (TX) A 2 is a product of the sequential metabolism of arachidonic acid by cyclo-oxygenases and TXA 2 synthase [13] . It exhibits a potent biological activity ranging from platelet secretion and aggregation, vaso-or broncho-constriction, and has been implicated in a number of cardiovascular and bronchial diseases. The biological effects of TXA 2 are mediated through membrane receptors that are identified as members of the GPCR superfamily, coupled mainly to Gα q [14] [15] [16] . Two variants of the TX receptor (TP), TPα and TPβ [17] , have been reported for the human receptor and are derived from an alternative splicing [18] [19] [20] .
Mitogenic and hypertrophic effects, and activation of mitogenactivated protein kinases (MAPKs) by TXA 2 analogues have been reported mainly in porcine and rat vascular smooth muscle cells [21] [22] [23] . We have demonstrated in porcine aortic smooth muscle cells that U46619, a TXA 2 analogue, induced c-Jun N-terminal kinase (JNK) activation and cyclo-oxygenase-2 expression in a protein kinase A (PKA)-dependent manner [24] . Recently, Gao et al. [25] have demonstrated in a human endothelial cell line, ECV304, that TXA 2 ligands trigger a PKC-, PTX-, Src-and EGFR-dependent activation of ERK. Miggin and Kinsella [26] reported in a human uterine smooth muscle cell line, ULTR, ERK activation by TX that was dependent on PKC, PKA, phosphoinositide 3-kinase and EGFRs, but was independent of PTX.
In the present study, we compared the activation of the human TP isoforms in human embryonic kidney HEK-293 cells. We demonstrated that, in human aortic smooth muscle cells (hASMCs), TP-induced activation of ERK is dependent on activation of the EGFR and partially on MMPs. Our results support the existence of cross-talk between TPs and RTKs in normal hASMCs involving MMPs, EGFR, Src kinase and PKC leading to ERK phosphorylation. 
MATERIALS AND METHODS

Materials
Cell culture
HEK-293 cells stably overexpressing TPα or TPβ were developed as previously described in [27] . Two clones were used expressing similar amounts of receptors (approx. 1.6 pmol/mg of total protein) [27] . Cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10 % (v/v) heat-inactivated foetal calf serum, 2 mM glutamine, 5 units/ml penicillin, under 5 % CO 2 at 37
• C containing 0.75 mg/ml geneticin. Cells were plated in 12-well plates for total inositol phosphate formation, in sixwell plates for immunoblotting or MAPK assay, and in 100 mmdiameter dishes for immunoprecipitation of EGFRs. Cells were serum-deprived for 24 h before stimulation. hASMCs were cultured in SmGM according to the manufacturer's instructions. Cells were used following the eighth passage and cultured to subconfluence.
Western blotting
Subconfluent cells (10 6 cells per well in six-well plates) were serum-deprived overnight in DMEM containing 0.5 % BSA and 20 mM Hepes, pH 7.4, for HEK-293 cells and for 36-72 hours for hASMCs in Clonetics smooth-muscle-cell basal medium (SmBM) containing 0.5 % BSA. The culture medium was changed and cells were kept for 1 h before the addition of agonist and various inhibitors. After incubation, cells were washed twice with PBS, pH 7.4, and lysed in 1 ml of ice-cold lysis buffer [50 mM Tris, pH 7.5, containing 1 % (v/v) Triton X-100, 100 mM NaCl, 40 mM sodium pyrophosphate, 50 mM sodium fluoride, 0.2 mM sodium orthovanadate, 1 µg/ml leupeptin, 5 mM EDTA and 1 µM benzamidine). Lysates were centrifuged at 10 000 g for 10 min at 4
• C, and the protein concentration in the resulting supernatant was determined by the micro-bicinchoninic acid ('BCA') assay (Pierce) using BSA as standard. Proteins (10 µg), prepared in Laemmli sample buffer, were separated by SDS/PAGE (10 % gels), and transferred on to nitrocellulose membranes in 25 mM Tris/HCl, 192 mM glycine buffer, pH 8. • C with a 1:5000 dilution of anti-(phosphorylated ERK) antibody. Membranes were washed five times for 10 min in Tris-buffered saline and incubated with a 1 in 5000 dilution of donkey anti-rabbit antibody coupled to horseradish peroxidase. Excess antibody was washed and positive bands were revealed by ECL , according to the manufacturer's instructions. All the membranes were stripped using the glycine/HCl buffer [0.2 M glycine, 0.1 % (w/v) SDS and 1 % (v/v) Tween 20], pH 2.2, before reprobing with anti-ERK polyclonal antibody (diluted 1 in 5000) to determine total ERK expression.
MAPK assay
MAPK assay was performed on immunoprecipitates of ERK [28, 29] . Cell lysates (500 µl at 0.5 mg/ml), prepared as described above, were incubated for 3 h at 4
• C with 1 µl of anti-ERK polyclonal antibody pre-adsorbed to protein A-Sepharose. Immune complexes were washed three times with lysis buffer and twice with kinase assay buffer (50 mM Hepes, pH 7.4, 5 mM magnesium acetate, 2 mM dithiothreitol, 1 mM EGTA and 0.2 mM sodium orthovanadate). MAPK activity was assayed by resuspending the final pellet in a total volume of 50 µl of kinase assay buffer containing myelin basic protein as substrate (0.5 mg/ml). Reactions were initiated by the addition of [γ -32 P]ATP (50 µM with unlabelled ATP; 3000 c.p.m./pmol specific radioactivity). After incubation at 30
• C for 15 min, assays were terminated by spotting 50 µl of the mix on to a 2 cm 2 -sized P-81 phosphocellulose paper. The papers were washed three times for 
min at 4
• C in orthophosphoric acid (1 %, w/v), once overnight at 4
• C and twice for 15 min at room temperature (25 • C). Papers were transferred into 6 ml plastic scintillation vials containing 4 ml of scintillation fluid and radioactivity was determined using a Beckman scintillation counter. Results were expressed in pmol of ATP/15 min per mg of protein.
Immunoprecipitation and immunoblotting of the EGFRs
Cells in 100 mm dishes were lysed in 1.5 ml of lysis buffer and centrifuged for 10 min at 14 000 g. Total protein samples (3 mg for IBOP-and 1 mg for EGF-activated cells) were mixed in a total volume of 1 ml with 15 µl of polyclonal anti-EGFR antibody coupled to agarose and incubated for 3 h at 4
• C. Immunoprecipitates were washed four times with lysis buffer, solubilized in Laemmli buffer, resolved by SDS/PAGE (7 % gel) and transferred on to nitrocellulose membranes. After blocking with 5 % (w/v) non-fat powdered milk in Tris-buffered saline, membranes were incubated with the anti-phosphotyrosine antibody (1:1000 dilution) for 1 h at room temperature, followed by a secondary antibody coupled to peroxidase (1:5000 dilution). Immunoreactive proteins were detected as described for ERK above. Membranes were stripped and reprobed with the polyclonal anti-EGFR antibody to ensure appropriate immunoprecipitation of the receptors.
Data analysis
Phosphorylated and total ERK were detected in each experiment. Autoradiograms were scanned using an Agfa Arcus II scanner and densitometric analyses were performed using SigmaGel (SPSS, Chicago, IL, U.S.A.). Statistical analysis of data was performed using a paired Student's t test.
RESULTS
Time-and dose-dependent activation of ERK1/2 by TX
The time-response and dose-response activation of ERK by each TP receptor isoform in response to IBOP, a stable analogue of TXA 2 , was compared. HEK-293 cells stably overexpressing TPα (HEK-293-TPα) or TPβ (HEK-293-TPβ) were used with comparable amounts of receptors as described previously [27] . The kinetics of phosphorylation of ERK1/2 were similar for the two TP isoforms. In fact, when HEK-293-TPα or HEK-293-TPβ cells were incubated with 100 nM IBOP, a rapid and transient activation of ERK1/2 MAPKs was obtained after detection with an antibody selective for the phosphorylated form of ERK1/2 ( Figure 1A ). HEK-293 cells transfected with the vector alone did not show any significant ERK1/2 phosphorylation in response to IBOP (results not shown). Furthermore, we checked the activity of ERK by assessing the phosphorylation of the myelin basic protein on immunoprecipitated ERK and observed results comparable with the Western blots of phosphorylated ERK ( Figure 1B ). In addition, IBOP induced the ERK1/2 activation in a dosedependent manner, with an EC 50 value of 0.16 + − 0.03 nM and 0.6 + − 0.2 nM for TPα and TPβ, respectively (n = 3).
Effect of SQ 29548 and PD98059 on ERK1/2 activation
SQ 29548, the highly selective antagonist of the TP receptors [30] , significantly inhibited ERK 1/2 activation in both HEK-293-TPα and HEK-293-TPβ cells, suggesting that this activation is mediated by the TP receptor (Figure 2A ). In addition, PD98059, a specific inhibitor of MAPK/ERK kinase 1 (MEK1), the kinase responsible for the phosphorylation of ERK1/2, blocked ERK activation. PD98059, which is not a protein kinase inhibitor, but a compound that stops Raf from activating MEK1, was described by Davies et al. [31] as a compound with an impressive selectivity profile to block the MAPK cascade. A 3.7 + − 0.98-fold increase over untreated cells was found with IBOP compared with a 1.2 + − 0.23-fold increase with IBOP + PD98059 for TPα, and a 5 + − 1.6-fold increase over untreated cells was found with IBOP compared with a 1.3 + − 0.2-fold increase with IBOP + PD98059 for TPβ (n = 3) ( Figure 2B ).
Role of PKC and Src in the activation of ERK1/2 by TPα and TPβ
The pathways involved in the TP-dependent activation of ERK were investigated further, using 5 µM GF109203X, a specific inhibitor of PKC. We have previously determined an optimal and selective concentration of GF109203X, i.e. 5 µM, in the same cells that blocked PMA-dependent phosphorylation of the TP isoforms [27] . When TPα-transfected cells were pretreated with GF109203X, TPα-dependent activation of ERK was partially decreased (a 4.6 + − 1.5-fold increase over untreated cells was found with IBOP compared with a 3.1 + − 1.1-fold increase with IBOP + GF109203X; n = 4) ( Figure 3A) . On the other hand, the PKC inhibitor significantly inhibited TPβ-induced ERK activation. IBOP induced a 6.2 + − 1.6-fold increase over untreated cells compared with a 2.6 + − 0.7-fold increase with IBOP + GF109203X (n = 4; P < 0.03), suggesting a role of PKC in ERK activation by TPβ rather than TPα. In these cells, as a positive control for the inhibitory effect of GF109203X, PMA was used. PMA-dependent activation of ERK activation was strongly inhibited by GF109203X ( Figure 3A) .
To examine the possible involvement of Src kinases in ERK activation by IBOP we used PP1, a highly selective Src kinase inhibitor, and assessed its regulatory effect on the TP-dependent activation of ERK. PP1 was first used at 3 and 10 µM, and an inhibitory effect was found at 10 µM. At this concentration, PP1 was able to inhibit both TPα-dependent ERK activation by 84 % (a 7.1-fold increase over untreated cells with IBOP compared with a 1.1-fold increase with IBOP + PP1) ( Figure 3B ). Furthermore, PP1 demonstrated an 81 % decrease in ERK phosphorylation for TPβ (a 13.8-fold increase over untreated cells with IBOP compared with a 2.6-fold increase with IBOP + PP1 for TPβ; n = 2) ( Figure 3B ). Similar results were obtained in HEK-293-TPα cells with a more recently described Src inhibitor, PP2, at 10 µM (a 4 + − 0.85-fold increase over untreated cells with IBOP compared with 1.5 + − 0.02 with IBOP + PP2; n = 3; P = 0.04). No significant effect was observed when cells were pretreated with 3 µM PP2 (a 3.2 + − 1-fold increase over untreated cells) or when cells were pre-treated with PP3, an inactive control for PP2 (a 4.2 + − 0.4-fold increase over untreated cells) (Figure 3C) , supporting the selectivity of the effect observed.
TPα-and TPβ-dependent ERK activation involves EGFR and MMP activation
Since EGFRs may link GPCRs to MAPK activation, we explored the role of the activation of these receptors in both TPα-and TPβ-dependent activation of ERK1/2. AG1478, a highly selective inhibitor of tyrosine-dependent phosphorylation of the EGFR, was used. TPα-and TPβ-dependent activation of ERK was strongly inhibited by 250 nM AG1478 ( Figure 4A ). For TPα, IBOP induced a 3.8 + − 0.2-fold increase in ERK activation over untreated cells compared with a 1.1 + − 0.2-fold increase with IBOP + AG1478 (n = 3; P < 0.02). For TPβ-expressing cells, a 16 + − 5-fold increase over untreated cells was obtained with IBOP compared with a 2.6 + − 0.7-fold increase with IBOP + AG1478 (n = 3; P < 0.02). As a positive control for the selectivity of the inhibition by AG1478, EGF was used, which showed a strong inhibition, whereas FGF-2-dependent ERK1/2 activation was not significantly modified ( Figure 4A) . To confirm the effect observed with AG1478, a structurally different inhibitor of the EGFR kinase activity, PD158780, was used at 250 nM, and similar results were obtained with IBOP [a 5 + − 1.02-fold increase over untreated cells with IBOP compared with a 1.9 + − 0.25-fold increase with IBOP + PD158780 (n = 3; partially blocked ERK phosphorylation in response to IBOP. A 6.6 + − 1-fold increase over basal levels resulted with IBOP compared with a 3 + − 0.3-fold increase with IBOP + BB2516 for TPα (n = 3; P < 0.04) ( Figure 5A ). Under these conditions, BB2516 did not modify EGF-dependent activation of ERK. This confirms that the effect observed with BB2516 is selective and is not because of a direct effect on EGFR. The ratio of phosphorylated ERK to total ERK was 1.1 + − 0.14 with EGF compared with 1.1 + − 0.2 with EGF + BB2516 (n = 6; P = 0.84). Furthermore, a neutralizing antibody for the HB-EGF decreased the ERK activation by IBOP, as shown for TPα in Figure 5(A) . Similarly, treatment of HEK-293-TPβ with 10 µM BB2516 partially blocked ERK phosphorylation in response to IBOP. A 6.6 + − 1.6-fold increase over basal cells resulted with IBOP compared with a 2.1 + − 0.8-fold increase with IBOP + BB2516 for TPβ (n = 3; P < 0.05) ( Figure 5B ).
Mechanisms involved in the phosphorylation of the EGFR by IBOP
To assess the direct involvement of TXA 2 in EGFR phosphorylation, HEK-293-TPα and HEK-293-TPβ cells were treated with IBOP and the phosphorylation of the immunoprecipitated EGFR on tyrosine residues was assayed. Figure 6 (A) shows that phosphorylation of EGFR was obtained for both TPα and TPβ and was blocked by both AG1478 and SQ 29548. Incubation of cells with EGF resulted in an increase in EGFR phosphorylation, which was inhibited by AG1478 ( Figure 6A ). We then checked whether activation of extracellular MMP is important in this transactivation.
IBOP-dependent phosphorylation of EGFR was also blocked when both HEK-293-TPα and HEK-293-TPβ cells were pre-treated with BB2516 ( Figure 6B ). Moreover, since PKC was implicated more in TPβ-rather than TPα-dependent activation of ERK, we checked whether activation of this kinase was involved in the phosphorylation of EGFRs. GF109203X, the PKC inhibitor, blocked this phosphorylation strongly in HEK-293-TPβ cells and to a lesser extent in HEK-293-TPα ( Figure 6B ).
Role of kinases, MMPs and Gα i in ERK phosphorylation by IBOP in hASMCs
The involvement of EGFR activation in the TP-dependent activation of ERK was tested in cultured hASMCs. As shown in Figure 7 (A), the TP antagonist SQ 29548 blocked IBOPdependent ERK activation. When cells were pre-treated with AG1478, the ERK activation was significantly suppressed, supporting the involvement of EGFR transactivation in these cells. In parallel experiments, we assessed the role of Src kinases, MMPs and PKC in ERK activation by IBOP. ERK activation in response to IBOP was partially, but significantly, decreased by BB2516 [a 1.9 + − 0.2-fold increase over untreated cells with IBOP compared with a 1.3 + − 0.2-fold increase with IBOP + BB2516 (n = 4; P < 0.001)] ( Figure 7B ). When cells were pre-treated for 30 min with 10 µM PP1 or 5 µM GF109203X, selective inhibitors of Src kinases and PKC respectively, ERK activation was considerably blocked [a 2 + − 0.17-fold increase over untreated cells with IBOP compared with a 0.73 + − 0.07-fold increase with IBOP + PP1 and a 1.14 + − 0.04-fold increase with IBOP + GF109203X (n = 4,5; P < 0.02)] ( Figure 7C ). In these experiments, we checked whether EGF-or PMA-dependent ERK activation was altered by these inhibitors. PP1, BB2516 and AG1478 had no effect on the activation of ERK by PMA (results not shown). Similarly, we verified that PP1, BB2516 and GF109203X did not modify EGF-dependent activation of ERK (results not shown).
Finally, the effect of PTX, a selective blocker of Gα i activation, on ERK activation was tested. When cells were pre-treated overnight with 100 ng/ml PTX, a decrease in ERK phosphorylation was observed in IBOP-treated cells [a 2.7 + − 0.5-fold increase over untreated cells with IBOP compared with a 1.4 + − 0.2-fold increase with IBOP + PTX (n = 4; P < 0.02)] ( Figure 7D ). As a positive control, we used LPA, described as coupling mainly Gα i in HEK-293 cells [32] , which showed a strong inhibition of ERK phosphorylation [a 4.8 + − 0.5-fold increase with LPA compared with a 0.8 + − 0.1-fold increase with LPA + PTX (n = 6; P < 0.001)] (Figure 7D ).
DISCUSSION
The major finding of this study is that TX-stimulated ERK is partially involved in activation of MMPs and EGFRs. In addition, using selective inhibitors, we demonstrated a role for PKC and Src kinases. In cells that overexpress either TPα or TPβ, we showed a major role of PKC in TPβ-dependent activation of ERK and EGFR phosphorylation, whereas PKC was less implicated in TPα signalling. A study that mentions the specificity and mechanism of action of some commonly used protein kinase inhibitors [31] asks us to pay attention to their use. Taking into account that most of our conclusions are drawn from the use of inhibitors of signalling, we have validated our results by using (i) structurally different inhibitors where possible, (ii) appropriate concentrations after having tested different concentrations and (iii) the inactive control for one inhibitor.
Activation of MAPKs is an important step in cell growth and differentiation for many growth factors and GPCRs. Activation of RTKs, such as EGFRs or PDGFRs, by GPCR ligands has been described in MAPK activation [33] . This transactivation of growth factor receptors leads to their association with adaptor proteins to form multicomplexes that lead to activation of the ERK pathway [4, 7, [34] [35] [36] . In some cell types, transactivation of EGFRs by GPCRs involved an increase in MMP activity with further cleavage of HB-EGF, which would then interact with the EGFR leading to intracellular signalling and activation of ERK [8] [9] [10] .
At the present time, only humans are known to have two TP isoforms, and the mechanisms involved in the regulation by each of these isoforms are not fully explored. In cell lines of animal origin, TX have been shown to activate ERK, p38 and JNK MAPKs, leading to hypertrophy, cell growth or gene expression [21, 37] . We carried out experiments to characterize the ERK activation by each TP isoform and evaluated the role of RTKs, non-RTKs, PKC and MMPs in ERK activation by a TX analogue. We showed that ERK activation in both HEK-293-TPα and HEK-293-TPβ, and in vascular smooth muscle cells is dependent on EGFR activation. This was demonstrated by using the highly selective inhibitor of EGFR phosphorylation, AG1478, and demonstrating the direct phosphorylation of the receptor on tyrosine residues in response to TX. To validate these results, we used a structurally different inhibitor, PD158780, and found the same effect. Recently, two reports have described in a human endothelial cell line ECV304 [25] and an endometrial cell line UTRL-1 [26] , that TP activation of ERK is dependent on EGFRs. However, these two studies were performed only in immortalized cell lines, where the amount of RTKs and signalling may differ considerably from primary cells.
One novel aspect of this report is the role of MMPs in ERK activation by TX. We showed that a synthetic MMP inhibitor, BB2516, blocked ERK activation by TX. This inhibitor attenuated EGFR phosphorylation in response to the two TP isoforms both in overexpressing systems and in hASMCs. We also demonstrated that anti-(HB-EGF) neutralizing antibody was able to decrease ERK activation in HEK-293-TPα. Our results suggest that MMPdependent processing of pro-HB-EGF could constitute one of the pathways linking TP to EGFR and ERK activation. The identity and activation mechanism of the MMP involved in this transactivation are unidentified. GPCRs activate a pathway that stimulates MMPs, most probably of the ADAM (a disintegrin and metalloproteinase-like) family that cleaves the pro-HB-EGF. It has been demonstrated that ADAM-9 or ADAM-12 could have a role in the shedding of the HB-EGF and the further activation of the EGFR [38] [39] [40] . In our effort to compare the intracellular pathways in response to TX activation, we showed that TPβ-dependent activation of ERK involves PKC, whereas for TPα, phosphorylation of ERK was less modified by PKC inhibitor. Our results suggest a difference in the regulation of intracellular signalling leading to ERK activation between the two isoforms, where PKC appeared to be more involved in EGFR activation by TPβ, but less by TPα. The analysis of EGFR phosphorylation of tyrosine residues and the phosphorylation of ERK showed similar results between both isoforms. This suggests that, for TPβ, PKCs are upstream of the EGFR subsequently leading to EGFR and ERK phosphorylation. For TPα, the mechanism seems different as other pathways might be involved. Miggin and Kinsella [41] have recently described a partial role of PKC in ERK activation by both TP isoforms, where PKC activates c-raf without involving the activation of EGFR.
TPα and TPβ differ in their C-terminal end. Although each of the HEK-293 cell expressing the TP isoforms expresses equal amounts of receptors, it is probable that the pathways triggered by these isoforms are different, due to the cytoplasmic C-terminal domain. At the present time, the major role described for these splice variants is in their difference in intracellular trafficking. It has been demonstrated that TPβ internalizes upon treatment with TX analogues whereas TPα does not [42] . Internalization might be responsible in part for triggering different intracellular pathways [43] . It can have a role in the activation of intracellular signalling, probably allowing contact between different proteins of the transduction cascade. One other possibility is the difference in the potency of TPα to activate ERK phosphorylation, since the EC 50 for activating ERK is higher than for TPβ.
In hASMCs, we demonstrated that TX implicates PKC in ERK activation. hASMCs have been shown by reverse-transcriptase PCR to express both TPα and TPβ [44] . Whether or not ERK activation in these cells occurs in response to one of the two isoforms is not presently known. PKC-dependent, partially dependent or -independent activation of ERK in response to different Gα-coupled receptors has been described: PKC involvement has been demonstrated for bradykinin [45] , the purinoreceptor P2Y2 [46] and M1 muscarinic receptors [47] , but not for angiotensin AT1 receptors [48] . PKC-dependent intracellular signalling has been described as divergent between the receptors and either regulates or not the transactivation between GPCRs and RTKs. For example, for bradykinin receptors [45] , PKC is not involved in EGFR transactivation and constitutes an independent pathway, whereas PKC activation is important in EGFR transactivation by the M1 muscarinic and P2Y2 receptors [46, 47] . Another type of regulation has been described where the PKC activation masks the transactivation of the EGFR by AT1 receptors in rat liver epithelial cell lines [49] .
Activation of tyrosine kinases, including Src family tyrosine kinases, has been implicated in the GPCR-dependent activation of MAPKs. Our results demonstrate that Src kinases and MMPs are critical in both TPα-and TPβ-transfected cells and in hASMCdependent activation of ERK1/2. PKC and Src kinases can contribute to MMP activation by other GPCRs, as demonstrated previously [39, 50] . This indeed depends on the receptor and cell type. However, a direct role of PKC on raf-1, which leads to ERK activation, cannot be ruled out. The regulation by Src kinases and the characterization of the PKC-dependent or -independent MMPs involved in EGFR transactivation in response to TX must await further investigation.
It is known from pharmacological and biochemical evidence that the TPs couple mainly Gα q [51, 52] and Gα 12/13 [53] ; Hirata et al. [20] have indicated that TPβ might couple Gα i proteins. Recently, Gao et al. [25] have described a new mechanism in the ECV 304 cell line for the transactivation of EGFR by TX, which required mainly Gα i , which in turn required PKC. In the present study, we showed that PTX-sensitive and -insensitive coupling are needed to activate ERK by TP in hASMCs.
TXA 2 has been shown to cause proliferation of vascular smooth muscle cells [54, 55] , endothelial cells, astrocytes and mesangial cells in vitro. Synergy has also been described between TPs and the PDGFR BB in rat vascular smooth muscle cells [54, 56] . Similarly, serotonin and U46619 react synergistically for the proliferation of aortic smooth muscle cells [57] . Other immediate early genes such as c-fos are expressed in response to GPCR ligands, such as thrombin or endothelin, and involve at least partial transactivation of the EGFR [12, [58] [59] [60] [61] .
In summary, we show that activation of ERK by TX involves EGFR transactivation and is partially dependent on metalloproteinase activation in cells that overexpress each of the TP isoforms and in hASMCs. The isoforms of TPs differ in ERK activation where TPβ-induced signalling has a greater dependency on PKC activation than TPα. A general model summarizing our results is proposed (Figure 8 ). Early events associated with mitogenesis could contribute to the cell proliferation induced by other factors, such as growth factors or other GPCR agonists. The role of activation of MMPs and EGFRs in cellular functions in response to TX awaits further investigation.
